Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001314083 | SCV001504598 | uncertain significance | Ataxia-telangiectasia syndrome | 2023-05-01 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 1015253). This variant has not been reported in the literature in individuals affected with ATM-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces tryptophan, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 308 of the ATM protein (p.Trp308Arg). |
Ambry Genetics | RCV004034307 | SCV005021400 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-03-10 | criteria provided, single submitter | clinical testing | The p.W308R variant (also known as c.922T>C), located in coding exon 7 of the ATM gene, results from a T to C substitution at nucleotide position 922. The tryptophan at codon 308 is replaced by arginine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. |